CoChat

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health

Open access

The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index; 53 of the 149 sources its claims cite were checked for support.

Abstract

Schizophrenia (SCZ) is a psychiatric disorder characterized by a wide range of positive, negative and cognitive symptoms, along with an increased risk of metabolic syndrome and cardiovascular disease that contribute to a 15-20-year reduced life expectancy. Autonomic dysfunction, in the form of increased sympathetic activity and decreased parasympathetic activity, is postulated to be implicated in SCZ and its treatment. The aim of this narrative review is to view SCZ through an autonomic lens and synthesize the evidence relating autonomic dysfunction to different domains of SCZ. Using various methods of assessing autonomic activity, autonomic dysfunction was found to be associated with multiple aspects of SCZ pathophysiology, including symptom severity, cognitive impairment, and the development of cardiometabolic comorbidities, such as metabolic syndrome and high BMI. The strongest association of low heart rate variability was noted among patients on antipsychotic treatment with high-affinity muscarinic antagonism (i.e., clozapine, olanzapine and quetiapine). The review will also suggest ways in which studying autonomic dysfunction can help reduce morbidity and mortality associated with SCZ and its treatment.

Overview

CoChat Summary

## TL;DR

This is a narrative review synthesizing evidence that schizophrenia is associated with autonomic nervous system dysfunction, especially reduced parasympathetic/vagal activity as measured by heart rate variability (HRV). The review argues that this dysfunction is linked to symptom severity, cognitive impairment, and cardiometabolic risk, with stronger HRV reductions often seen in patients taking clozapine, olanzapine, or quetiapine.

## Key findings

  • Across studies, patients with schizophrenia had reduced HRV and vagal cardiac control compared with healthy controls; a meta-analytic review of 34 studies found significantly lower HF-HRV and RMSSD in schizophrenia.
  • Autonomic dysfunction was associated with symptom severity: higher PANSS scores were negatively correlated with SDNN and RMSSD, and negative symptoms were inversely related to RMSSD and HF while positively associated with LF/HF.
  • For cognition, one EDA study found that EDA non-responders had worse performance on verbal comprehension/fluency, memory, perceptual organization, psychomotor function, abstract reasoning, and executive function; another study found no significant difference on MATRICS between responders and non-responders.
  • For cardiometabolic outcomes, lower HRV was linked to risk factors such as hypertension, diabetes, and high cholesterol in schizophrenia samples, but one large correlational study found no HRV difference between schizophrenia patients with versus without metabolic syndrome.

## Methods

  • Narrative review of the literature on autonomic dysfunction in schizophrenia, with emphasis on HRV and, where relevant, other autonomic measures such as EDA, SAA, catecholamines, and orthostatic cardiovascular responses.
  • The review synthesized studies comparing schizophrenia vs healthy controls and, where available, medicated vs unmedicated patients, including evidence on symptom severity, cognition, and cardiometabolic comorbidity.
  • Main analysis was qualitative synthesis of prior studies and meta-analytic findings; no new primary sample or original statistical analysis was reported.

## Limitations

  • The paper states that the evidence base is limited by the largely cross-sectional nature of the literature, making causality difficult to determine.
  • It also notes that whether autonomic dysfunction is intrinsic to schizophrenia or secondary to antipsychotic treatment “has yet to be fully elucidated.”
  • Evident from the text: findings across autonomic measures are inconsistent in places (for example, EDA responder/non-responder results and some HRV-symptom correlations), which weakens certainty about some associations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41537-021-00151-6

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Summary of sympathovagal balance in schizophrenia. Studies of heart rate variability (HRV) use the LF/HF ratio as a proxy for estimating sympathetic activity. HRV studies in schizophrenia have found contradictory findings in terms of the LF/HF ratio. In some instances, autonomic dysfunction in SCZ can be characterized as a decreased parasympathetic functioning while maintaining relatively normal sympathetic activation (~LF/HF ratio). In other cases, the LF/HF ratio is elevated. This may represent two different scenarios: (1) increased sympathetic activation (high LF numerator) or (2) decreased parasympathetic activation (low HF denominator), leading to sympathetic dominance.
Fig. 1 Summary of sympathovagal balance in schizophrenia. Studies of heart rate variability (HRV) use the LF/HF ratio as a proxy for estimating sympathetic activity. HRV studies in schizophrenia have found contradictory findings in terms of the LF/HF ratio. In some instances, autonomic dysfunction in SCZ can be characterized as a decreased parasympathetic functioning while maintaining relatively normal sympathetic activation (~LF/HF ratio). In other cases, the LF/HF ratio is elevated. This may represent two different scenarios: (1) increased sympathetic activation (high LF numerator) or (2) decreased parasympathetic activation (low HF denominator), leading to sympathetic dominance.CC BY · PubMed Central
Fig. 2 Antipsychotic properties and their effects on autonomic functioning and heart rate variability. The differing effects of antipsychotics (AP) on autonomic dysfunction and heart rate variability (HRV) may be dependent on the pharmacokinetic properties of the APs (i.e. their affinities for cholinergic and adrenergic receptors).
Fig. 2 Antipsychotic properties and their effects on autonomic functioning and heart rate variability. The differing effects of antipsychotics (AP) on autonomic dysfunction and heart rate variability (HRV) may be dependent on the pharmacokinetic properties of the APs (i.e. their affinities for cholinergic and adrenergic receptors).CC BY · PubMed Central
Fig. 3 The Neurovisceral Integration Hypothesis. a Cognitive and emotion processing functions are regulated by brain systems also involved in the regulation of the autonomic nervous system. The Neurovisceral Integration Hypothesis asserts that the prefrontal cortex (PFC) exerts tonic inhibition over limbic brain regions (curved red line) that typically suppress parasympathetic responses (straight red line) and activate sympathetic responses (straight green arrow). b In schizophrenia, deficits in the PFC may lead to disinhibition of the amygdala and medullary regions (orange lines) during situations of emotional or social processing. This results in suppression of parasympathetic activity and stimulation of sympathetic activity, thereby causing increased heart rate and decreased heart rate variability. This may potentially be an explanatory mechanism underlying the correlation between decreased HRV and reduced PFC activity.
Fig. 3 The Neurovisceral Integration Hypothesis. a Cognitive and emotion processing functions are regulated by brain systems also involved in the regulation of the autonomic nervous system. The Neurovisceral Integration Hypothesis asserts that the prefrontal cortex (PFC) exerts tonic inhibition over limbic brain regions (curved red line) that typically suppress parasympathetic responses (straight red line) and activate sympathetic responses (straight green arrow). b In schizophrenia, deficits in the PFC may lead to disinhibition of the amygdala and medullary regions (orange lines) during situations of emotional or social processing. This results in suppression of parasympathetic activity and stimulation of sympathetic activity, thereby causing increased heart rate and decreased heart rate variability. This may potentially be an explanatory mechanism underlying the correlation between decreased HRV and reduced PFC activity.CC BY · PubMed Central
Fig. 4 Implications of autonomic nervous system dysfunction in schizophrenia. Autonomic dysfunction, in the form of increased sympathetic activity and decreased parasympathetic activity, has been implicated in various disease states. Autonomic dysfunction, as assessed through heart rate variability (HRV) and other assessment methods, has been related to various domains of SCZ, including psychopathology, cognitive functioning, cardiometabolic risk, and microbiome changes. The relationship between these domains and autonomic functioning is believed to be bidirectional. SCZ Schizophrenia, HR heart rate, HRV heart rate variability.
Fig. 4 Implications of autonomic nervous system dysfunction in schizophrenia. Autonomic dysfunction, in the form of increased sympathetic activity and decreased parasympathetic activity, has been implicated in various disease states. Autonomic dysfunction, as assessed through heart rate variability (HRV) and other assessment methods, has been related to various domains of SCZ, including psychopathology, cognitive functioning, cardiometabolic risk, and microbiome changes. The relationship between these domains and autonomic functioning is believed to be bidirectional. SCZ Schizophrenia, HR heart rate, HRV heart rate variability.CC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 1 Not valid · 64 Not checked · 13 Own results and interpretations

67 more claims · 25 with their cited sources checked

Create a free account to see all 127 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 45
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Citations

Cites

Show all 112 references

Cited by

See all 98

Metadata

Authors
Stogios, N., Gdanski, A., Gerretsen, P., Chintoh, A. F., Graff-Guerrero, A., Rajji, T. K., Remington, G., Hahn, M. K., & Agarwal, S. M.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • University of Toronto (CA)
Corresponding author
Agarwal, Sri Mahavir
Venue
npj Schizophrenia
Published
2021-04-26
Volume
7
Issue
1
Pages
22-22
ISSN
2334-265X (ISSN-L)
OpenAlex
W3157256311
Cited by
98
References
112
Citations by year
2026: 13 · 2025: 29 · 2024: 20 · 2023: 12 · 2022: 18 · 2021: 6
FWCI
2.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Schizophrenia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Physicians' Services Incorporated Foundation
  • University of Toronto
  • Department of Psychiatry, University of Toronto (PJT-153262)
  • Canadian Institutes of Health Research (153262_1)
  • Banting and Best Diabetes Centre, University of Toronto (PJT-153262)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
autonomic dysfunction, cognitive impairment, metabolic syndrome, cardiometabolic comorbidities, heart rate variability, sympathetic activity, parasympathetic activity, antipsychotic drugs, muscarinic antagonism, clozapine, olanzapine, quetiapine, body mass index, cardiovascular disease, life expectancy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. https://app.cochat.ai/papers/10.1038/s41537-021-00151-6
The paper
Stogios, N., Gdanski, A., Gerretsen, P., Chintoh, A. F., Graff-Guerrero, A., Rajji, T. K., Remington, G., Hahn, M. K., & Agarwal, S. M. (2021). Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. npj Schizophrenia. https://doi.org/10.1038/s41537-021-00151-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.